The main purpose of this study is to explore the role of Swertianin in MASLD and its mechanisms, particularly its potential to inhibit M1-type macrophage polarization by activating the peroxisome proliferator-activated receptor-γ (PPARG) pathway. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.